Stephane Heymans

List of Publications by Year
in descending order

238 papers	35,691 citations	7096 78 h-index	3650 180 g-index
243 all docs	243 docs citations	243 times ranked	32183 citing authors

#	Article	IF	Citations
1	Neutrophil inhibition improves acute inflammation in a murine model of viral myocarditis. Cardiovascular Research, 2023, 118, 3331-3345.	3.8	10
2	Diagnostic value of echocardiographic markers for diastolic dysfunction and heart failure with preserved ejection fraction. Heart Failure Reviews, 2022, 27, 207-218.	3.9	15
3	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. European Journal of Preventive Cardiology, 2022, 29, 275-300.	1.8	11
4	Pathophysiology of Takotsubo syndromeÂâ€“ a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of the European Society of CardiologyÂâ€“ÂPart 2: vascular pathophysiology, gender and sex hormones, genetics, chronic cardiovascular problems and clinical implications. European Journal of Heart Failure, 2022, 24, 274-286.	7.1	34
5	Biomarkerâ€based assessment of collagen crossâ€linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the <scp>HOMAGE</scp> clinical trial. European Journal of Heart Failure, 2022, 24, 321-331.	7.1	16
6	NOX1 mediates metabolic heart disease in mice and is upregulated in monocytes of humans with diastolic dysfunction. Cardiovascular Research, 2022, 118, 2973-2984.	3.8	10
7	Stabilin-1 mediates beneficial monocyte recruitment and tolerogenic macrophage programming during CVB3-induced viral myocarditis. Journal of Molecular and Cellular Cardiology, 2022, 165, 31-39.	1.9	7
8	Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC). European Journal of Heart Failure, 2022, 24, 406-420.	7.1	22
9	Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC Working Group on Myocardial Function and the ESC Working Group on Cellular Biology of the Heart. Cardiovascular Research, 2022, 118, 3016-3051.	3.8	30
10	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. European Journal of Heart Failure, 2022, 24, 143-168.	7.1	41
11	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	7.1	820
12	Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms. Nature Reviews Cardiology, 2022, 19, 75-77.	13.7	171
13	Pathophysiology of <scp>T</scp>akotsubo syndromeÂâ€“Âa joint scientific statement from the Heart Failure Association <scp>T</scp>akotsubo Syndrome Study Group and Myocardial Function Working Group of the <scp>E</scp>uropean Society of CardiologyÂâ€“ÂPart 1: overview and the central role for catecholamines and sympathetic nervous system. European Journal of Heart Failure, 2022, 24, 257-273.	7.1	36
14	Immunometabolic mechanisms of heart failure with preserved ejection fraction. , 2022, 1, 211-222.		27
15	Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the <scp>HOMAGE</scp> trial. European Journal of Heart Failure, 2022, 24, 771-778.	7.1	7
16	Global Longitudinal Strain is Incremental to Left Ventricular Ejection Fraction for the Prediction of Outcome in Optimally Treated Dilated Cardiomyopathy Patients. Journal of the American Heart Association, 2022, 11, e024505.	3.7	21
17	Comparing and contrasting risk factors for heart failure in patients with and without history of myocardial infarction: data from <scp>HOMAGE</scp> and the <scp>UK</scp> Biobank. European Journal of Heart Failure, 2022, 24, 976-984.	7.1	5
18	Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology. European Heart Journal, 2022, 43, 863-867.	2.2	14

#	Article	IF	Citations
19	AAV9-mediated functional screening for cardioprotective cytokines in Coxsackievirus-B3-induced myocarditis. Scientific Reports, 2022, 12, 7304.	3.3	2
20	Integrated Analysis of Cancer Tissue and Vitreous Humor from Retinoblastoma Eyes Reveals Unique Tumor-Specific Metabolic and Cellular Pathways in Advanced and Non-Advanced Tumors. Cells, 2022, 11, 1668.	4.1	7
21	Global longitudinal strain by <scp>CMR</scp> improves prognostic stratification in acute myocarditis presenting with normal <scp>LVEF</scp>. European Journal of Clinical Investigation, 2022, 52, .	3.4	6
22	The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial. European Journal of Heart Failure, 2022, 24, 1559-1568.	7.1	12
23	The <scp>HFAâ€PEFF</scp> and <scp>H₂FPEF</scp> scores largely disagree in classifying patients with suspected heart failure with preserved ejection fraction. European Journal of Heart Failure, 2021, 23, 838-840.	7.1	35
24	Unlocking the Value of White Blood Cells for Heart Failure Diagnosis. Journal of Cardiovascular Translational Research, 2021, 14, 53-62.	2.4	12
25	Towards standardization of echocardiography for the evaluation of left ventricular function in adult rodents: a position paper of the ESC Working Group on Myocardial Function. Cardiovascular Research, 2021, 117, 43-59.	3.8	72
26	Phenotypic clustering of dilated cardiomyopathy patients highlights important pathophysiological differences. European Heart Journal, 2021, 42, 162-174.	2.2	62
27	Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nature Reviews Cardiology, 2021, 18, 169-193.	13.7	589
28	Linagliptin prevents left ventricular stiffening by reducing titin cleavage and hypophosphorylation. Journal of Cellular and Molecular Medicine, 2021, 25, 729-741.	3.6	6
29	2020 ESC Guidelines for the management of adult congenital heart disease. European Heart Journal, 2021, 42, 563-645.	2.2	971
30	Intravenous immunoglobulin therapy in adult patients with idiopathic chronic cardiomyopathy and cardiac parvovirus <scp>B19</scp> persistence: a prospective, doubleâ€blind, randomized, placeboâ€controlled clinical trial. European Journal of Heart Failure, 2021, 23, 302-309.	7.1	24
31	AMPKÎ±1 deletion in myofibroblasts exacerbates post-myocardial infarction fibrosis by a connexin 43 mechanism. Basic Research in Cardiology, 2021, 116, 10.	5.9	26
32	Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. European Journal of Heart Failure, 2021, 23, 527-540.	7.1	37
33	Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2021, 42, 1554-1568.	2.2	434
34	Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology <scp>W</scp>orking <scp>G</scp>roup on <scp>M</scp>yocardial and <scp>P</scp>ericardial <scp>D</scp>iseases. European Journal of Heart Failure, 2021, 23, 512-526.	7.1	153
35	Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, , .	3.0	4
36	Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. JACC: Heart Failure, 2021, 9, 268-277.	4.1	46

#	Article	IF	Citations
37	Toll-Like Receptors: Are They Taking a Toll on the Heart in Viral Myocarditis?. Viruses, 2021, 13, 1003.	3.3	5
38	Intravitreal injection of anti-miRs against miR-142-3p reduces angiogenesis and microglia activation in a mouse model of laser-induced choroidal neovascularization. Aging, 2021, 13, 12359-12377.	3.1	9
39	Understanding the genetics of adult-onset dilated cardiomyopathy: what a clinician needs to know. European Heart Journal, 2021, 42, 2384-2396.	2.2	28
40	Identification of sexâ€specific biomarkers predicting newâ€onset heart failure. ESC Heart Failure, 2021, 8, 3512-3520.	3.1	11
41	Postâ€discharge arrhythmic risk stratification of patients with acute myocarditis and lifeâ€threatening ventricular tachyarrhythmias. European Journal of Heart Failure, 2021, 23, 2045-2054.	7.1	17
42	Valproic acid stimulates myogenesis in pluripotent stem cell-derived mesodermal progenitors in a NOTCH-dependent manner. Cell Death and Disease, 2021, 12, 677.	6.3	10
43	Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial. Cardiovascular Diabetology, 2021, 20, 163.	6.8	7
44	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	2.2	5,558
45	Reciprocal organ interactions during heart failure: a position paper from the ESC Working Group on Myocardial Function. Cardiovascular Research, 2021, 117, 2416-2433.	3.8	27
46	The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart â€˜OMicsâ€™ in AGEing (HOMAGE) randomized clinical trial. European Heart Journal, 2021, 42, 684-696.	2.2	77
47	The prognostic impact of mechanical atrial dysfunction and atrial fibrillation in heart failure with preserved ejection fraction. European Heart Journal Cardiovascular Imaging, 2021, 23, 74-84.	1.2	17
48	Correlation of Volume of Macular Edema with Retinal Tomography Features in Diabetic Retinopathy Eyes. Journal of Personalized Medicine, 2021, 11, 1337.	2.5	1
49	The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial. Journal of Cardiac Failure, 2021, , .	1.7	3
50	100â€ƒGlobal longitudinal strain by CMR improves prognostic stratification in acute myocarditis presenting with normal LVEF. European Heart Journal Supplements, 2021, 23, .	0.1	1
51	Plasma protein biomarkers and their association with mutually exclusive cardiovascular phenotypes: the FIBRO-TARGETS caseâ€“control analyses. Clinical Research in Cardiology, 2020, 109, 22-33.	3.3	19
52	Response to â€˜The possible role of insulin and glucagon in patients with heart failure and Type 2 diabetesâ€™. European Heart Journal, 2020, 41, 326-327.	2.2	1
53	Validation of the HFAâ€PEFF score for the diagnosis of heart failure with preserved ejection fraction. European Journal of Heart Failure, 2020, 22, 413-421.	7.1	101
54	<scp>Heart Failure Association</scp> of the <scp>European Society of Cardiology</scp> update on sodiumâ€“glucose coâ€transporter 2 inhibitors in heart failure. European Journal of Heart Failure, 2020, 22, 1984-1986.	7.1	66

#	Article	IF	Citations
55	Network integration and modelling of dynamic drug responses at multi-omics levels. Communications Biology, 2020, 3, 573.	4.4	28
56	The effect of different anaesthetics on echocardiographic evaluation of diastolic dysfunction in a heart failure with preserved ejection fraction model. Scientific Reports, 2020, 10, 15701.	3.3	8
57	Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. Cardiovascular Research, 2020, 116, 1820-1834.	3.8	51
58	Selective NADH communication from Î±-ketoglutarate dehydrogenase to mitochondrial transhydrogenase prevents reactive oxygen species formation under reducing conditions in the heart. Basic Research in Cardiology, 2020, 115, 53.	5.9	28
59	Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the <scp>Translational Research Committee</scp> of the <scp>Heart Failure Association</scp> (<scp>HFA</scp>) of the <scp>European Society of Cardiology</scp> (<scp>ESC</scp>). European Journal of Heart Failure, 2020, 22, 2272-2289.	7.1	92
60	Prednisone and azathioprine in patients with inflammatory cardiomyopathy: systematic review and metaâ€analysis. ESC Heart Failure, 2020, 7, 2278-2296.	3.1	4
61	Anthracycline-Related Heart Failure: Certain Knowledge and Open Questions. Current Heart Failure Reports, 2020, 17, 357-364.	3.3	8
62	Vascular ring anomaly in a patient with phosphomannomutase 2 deficiency: A case report and review of the literature. JIMD Reports, 2020, 56, 27-33.	1.5	3
63	A directed network analysis of the cardiome identifies molecular pathways contributing to the development of HFpEF. Journal of Molecular and Cellular Cardiology, 2020, 144, 66-75.	1.9	16
64	High-Sensitivity Troponin-T and Cardiovascular Outcomes in the Community: Differences Between Women and Men. Mayo Clinic Proceedings, 2020, 95, 1158-1168.	3.0	10
65	Non-coding RNAs: update on mechanisms and therapeutic targets from the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. Cardiovascular Research, 2020, 116, 1805-1819.	3.8	39
66	Microvascular and lymphatic dysfunction in HFpEF and its associated comorbidities. Basic Research in Cardiology, 2020, 115, 39.	5.9	77
67	Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the <scp>H</scp>eart <scp>F</scp>ailure <scp>A</scp>ssociation (<scp>HFA</scp>), the <scp>E</scp>uropean <scp>A</scp>ssociation of <scp>C</scp>ardiovascular <scp>I</scp>maging (<scp>EACVI</scp>) and the <scp>Cardioâ€Oncology C</scp>ouncil of the <scp>E</scp>uropean <scp>S</scp>ociety of <scp>C</scp>ardiology (<scp>ESC</scp>). European Journal of Heart Failure, 2020, 22, 1504-1524.	7.1	234
68	Enhanced clinical phenotyping by mechanistic bioprofiling in heart failure with preserved ejection fraction: insights from the MEDIA-DHF study (The Metabolic Road to Diastolic Heart Failure). Biomarkers, 2020, 25, 201-211.	1.9	26
69	Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proofâ€ofâ€conceptâ€, randomised, precisionâ€medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial. European Journal of Heart Failure, 2020, 22, 1711-1723.	7.1	43
70	Arrhythmic risk stratification in non-ischaemic dilated cardiomyopathy beyond ejection fraction. Heart, 2020, 106, 656-664.	2.9	21
71	Regulatory RNAs in Heart Failure. Circulation, 2020, 141, 313-328.	1.6	133
72	Cellular and Molecular Differences between HFpEF and HFrEF: A Step Ahead in an Improved Pathological Understanding. Cells, 2020, 9, 242.	4.1	176

#	Article	IF	Citations
73	The Missing â€œlncâ€•between Genetics and Cardiac Disease. Non-coding RNA, 2020, 6, 3.	2.6	5
74	Unraveling the Molecular Mechanism of Action of Empagliflozin in HeartÂFailure With Reduced Ejection Fraction WithÂorÂWithout Diabetes. JACC Basic To Translational Science, 2019, 4, 831-840.	4.1	65
75	Balance of Active, Passive, and Anatomical Cardiac Properties in Doxorubicin-Induced Heart Failure. Biophysical Journal, 2019, 117, 2337-2348.	0.5	6
76	Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 272-285.	7.1	182
77	Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. European Journal of Heart Failure, 2019, 21, 827-843.	7.1	223
78	Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure. Circulation: Heart Failure, 2019, 12, e005897.	3.9	63
79	Functional Screening Identifies MicroRNAs as Multi-Cellular Regulators of Heart Failure. Scientific Reports, 2019, 9, 6055.	3.3	26
80	The continuous heart failure spectrum: moving beyond an ejection fraction classification. European Heart Journal, 2019, 40, 2155-2163.	2.2	195
81	Extracellular SPARC increases cardiomyocyte contraction during health and disease. PLoS ONE, 2019, 14, e0209534.	2.5	19
82	Catalyzing Transcriptomics Research in Cardiovascular Disease: The CardioRNA COST Action CA17129. Non-coding RNA, 2019, 5, 31.	2.6	14
83	AntagomiR-103 and -107 Treatment Affects Cardiac Function and Metabolism. Molecular Therapy - Nucleic Acids, 2019, 14, 424-437.	5.1	25
84	Treatments targeting inotropy. European Heart Journal, 2019, 40, 3626-3644.	2.2	123
85	Immunosuppressive Therapy Improves Both Short- and Long-Term Prognosis in Patients With Virus-Negative Nonfulminant Inflammatory Cardiomyopathy. Circulation: Heart Failure, 2018, 11, e004228.	3.9	65
86	Titin cardiomyopathy leads to altered mitochondrial energetics, increased fibrosis and long-term life-threatening arrhythmias. European Heart Journal, 2018, 39, 864-873.	2.2	132
87	The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC. European Journal of Heart Failure, 2018, 20, 445-459.	7.1	118
88	MicroRNA-221/222 Family Counteracts Myocardial Fibrosis in Pressure Overloadâ€“Induced Heart Failure. Hypertension, 2018, 71, 280-288.	2.7	128
89	The forkhead transcription factor Foxo3 negatively regulates natural killer cell function and viral clearance in myocarditis. European Heart Journal, 2018, 39, 876-887.	2.2	22
90	Prevalence of Pathogenic Gene Mutations and Prognosis Do Not Differ in Isolated Left Ventricular Dysfunction Compared With Dilated Cardiomyopathy. Circulation: Heart Failure, 2018, 11, e004682.	3.9	22

#	Article	IF	Citations
91	PD-(L)1 Inhibition and Cardiac Damage: A Relevant Toxicity?. Journal of Thoracic Oncology, 2018, 13, 478-479.	1.1	4
92	Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives. European Heart Journal, 2018, 39, 2704-2716.	2.2	300
93	Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 16-37.	7.1	239
94	Osteoglycin prevents the development of age-related diastolic dysfunction during pressure overload by reducing cardiac fibrosis and inflammation. Matrix Biology, 2018, 66, 110-124.	3.6	39
95	Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis. ESC Heart Failure, 2018, 5, 139-148.	3.1	21
96	A model-based assay design to reproduce in vivo patterns of acute drug-induced toxicity. Archives of Toxicology, 2018, 92, 553-555.	4.2	23
97	An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 216-227.	7.1	81
98	Mutations in LZTR1 drive human disease by dysregulating RAS ubiquitination. Science, 2018, 362, 1177-1182.	12.6	133
99	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Associationâ€“European Society of Cardiology. European Heart Journal, 2018, 39, 4243-4254.	2.2	171
100	Heart Failure WithÂRecovered Ejection Fraction. Journal of the American College of Cardiology, 2018, 72, 1557-1558.	2.8	20
101	MicroRNA-155 Amplifies Nitric Oxide/cGMP Signaling and Impairs Vascular Angiotensin II Reactivity in Septic Shock. Critical Care Medicine, 2018, 46, e945-e954.	0.9	22
102	Non-coding RNAs in vascular disease â€“ from basic science to clinical applications: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology. Cardiovascular Research, 2018, 114, 1281-1286.	3.8	37
103	Complex roads from genotype to phenotype in dilated cardiomyopathy: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology. Cardiovascular Research, 2018, 114, 1287-1303.	3.8	91
104	Sexâ€specific associations of obesity and Nâ€terminal proâ€Bâ€type natriuretic peptide levels in the general population. European Journal of Heart Failure, 2018, 20, 1205-1214.	7.1	60
105	Scientific updates on the interaction of genes, epigenetics, and multicellularity in cardiovascular diseases: the Working Group of Myocardial Function of the ESC. Cardiovascular Research, 2018, 114, 1271-1272.	3.8	3
106	NF-ÎºB-mediated metabolic remodelling in the inflamed heart in acute viral myocarditis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 2579-2589.	3.8	27
107	SPARC preserves endothelial glycocalyx integrity, and protects against adverse cardiac inflammation and injury during viral myocarditis. Matrix Biology, 2018, 74, 21-34.	3.6	22
108	Resistance to retinopathy development in obese, diabetic and hypertensive ZSF1 rats: an exciting model to identify protective genes. Scientific Reports, 2018, 8, 11922.	3.3	4

#	Article	IF	Citations
109	Metabolic changes in hypertrophic cardiomyopathies: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology. Cardiovascular Research, 2018, 114, 1273-1280.	3.8	64
110	Lymphocytic myocarditis occurs with myocardial infarction and coincides with increased inflammation, hemorrhage and instability in coronary artery atherosclerotic plaques. International Journal of Cardiology, 2017, 232, 53-62.	1.7	15
111	Heart failure with preserved ejection fraction: a nephrologist-directed primer. Heart Failure Reviews, 2017, 22, 765-773.	3.9	14
112	Reply to the letter to the editor â€œIs colchicine really harmful in viral myocarditis?â€• International Journal of Cardiology, 2017, 229, 43.	1.7	0
113	Sema3A promotes the resolution of cardiac inflammation after myocardial infarction. Basic Research in Cardiology, 2017, 112, 42.	5.9	62
114	Inhibition of MicroRNA-146a and Overexpression of Its Target Dihydrolipoyl Succinyltransferase Protect Against Pressure Overload-Induced Cardiac Hypertrophy and Dysfunction. Circulation, 2017, 136, 747-761.	1.6	53
115	CD45 is a more sensitive marker than CD3 to diagnose lymphocytic myocarditis in the endomyocardium. Human Pathology, 2017, 62, 83-90.	2.0	11
116	The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2017, 19, 1361-1378.	7.1	115
117	Propionic acidemia as a cause of adult-onset dilated cardiomyopathy. European Journal of Human Genetics, 2017, 25, 1195-1201.	2.8	25
118	Cartilage intermediate layer protein 1 (CILP1): A novel mediator of cardiac extracellular matrix remodelling. Scientific Reports, 2017, 7, 16042.	3.3	37
119	Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. European Heart Journal, 2017, 38, 2649-2662.	2.2	163
120	A novel 72-kDa leukocyte-derived osteoglycin enhances the activation of toll-like receptor 4 and exacerbates cardiac inflammation during viral myocarditis. Cellular and Molecular Life Sciences, 2017, 74, 1511-1525.	5.4	28
121	Long Non-Coding RNA Malat-1 Is Dispensable during Pressure Overload-Induced Cardiac Remodeling and Failure in Mice. PLoS ONE, 2016, 11, e0150236.	2.5	42
122	Renal function estimation and Cockcroftâ€“Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart â€˜OMicsâ€™ in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives. BMC Medicine, 2016, 14, 181.	5.5	48
123	Colchicine aggravates coxsackievirus B3 infection in mice. International Journal of Cardiology, 2016, 216, 58-65.	1.7	25
124	Perimyocarditis Complicated by Early Development ofÂConstrictive Pericarditis. Canadian Journal of Cardiology, 2016, 32, 395.e11-395.e12.	1.7	0
125	The diverse functions of osteoglycin: a deceitful dwarf, or a master regulator of disease?. FASEB Journal, 2016, 30, 2651-2661.	0.5	56
126	The Network Library: a framework to rapidly integrate network biology resources. Bioinformatics, 2016, 32, i473-i478.	4.1	8

#	Article	IF	Citations
127	RNA Profiling in Human and Murine Transplanted Hearts: Identification and Validation of Therapeutic Targets for Acute Cardiac and Renal Allograft Rejection. American Journal of Transplantation, 2016, 16, 99-110.	4.7	49
128	The Quest for New Approaches inÂMyocarditis and InflammatoryÂCardiomyopathy. Journal of the American College of Cardiology, 2016, 68, 2348-2364.	2.8	257
129	Metabolic support for the heart: complementary therapy for heart failure?. European Journal of Heart Failure, 2016, 18, 1420-1429.	7.1	81
130	Relevance of cardiac parvovirus <scp>B19</scp> in myocarditis and dilated cardiomyopathy: review of the literature. European Journal of Heart Failure, 2016, 18, 1430-1441.	7.1	108
131	Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. European Heart Journal, 2016, 37, 1850-1858.	2.2	757
132	Ventricular myocarditis coincides with atrial myocarditis in patients. Cardiovascular Pathology, 2016, 25, 141-148.	1.6	31
133	Long noncoding RNAMALAT1-derived mascRNA is involved in cardiovascular innate immunity. Journal of Molecular Cell Biology, 2016, 8, 178-181.	3.3	55
134	miR-21 promotes fibrosis in an acute cardiac allograft transplantation model. Cardiovascular Research, 2016, 110, 215-226.	3.8	61
135	Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential. European Journal of Heart Failure, 2015, 17, 764-771.	7.1	109
136	Breeding Strategy Determines Rupture Incidence in Post-Infarct Healing WARPing Cardiovascular Research. PLoS ONE, 2015, 10, e0139199.	2.5	4
137	Myocardial scar predicts monomorphic ventricular tachycardia but not polymorphic ventricular tachycardia or ventricular fibrillation in nonischemic dilated cardiomyopathy. Heart Rhythm, 2015, 12, 2106-2114.	0.7	67
138	cyNeo4j: connecting Neo4j and Cytoscape. Bioinformatics, 2015, 31, 3868-3869.	4.1	22
139	Osteoglycin Prevents Cardiac Dilatation and Dysfunction After Myocardial Infarction Through Infarct Collagen Strengthening. Circulation Research, 2015, 116, 425-436.	4.5	75
140	The RNA-binding protein HuR is essential for the B cell antibody response. Nature Immunology, 2015, 16, 415-425.	14.5	125
141	The microRNA-221/-222 cluster balances the antiviral and inflammatory response in viral myocarditis. European Heart Journal, 2015, 36, 2909-2919.	2.2	95
142	Prevalence and prognostic relevance of cardiac involvement in ANCA-associated vasculitis: Eosinophilic granulomatosis with polyangiitis and granulomatosis with polyangiitis. International Journal of Cardiology, 2015, 199, 170-179.	1.7	104
143	Long noncoding RNAs in cardiac development and ageing. Nature Reviews Cardiology, 2015, 12, 415-425.	13.7	296
144	Advances in Toll-like receptor biology: Modes of activation by diverse stimuli. Critical Reviews in Biochemistry and Molecular Biology, 2015, 50, 359-379.	5.2	71

#	Article	IF	Citations
145	Liver X receptor activation enhances CVB3 viral replication during myocarditis by stimulating lipogenesis. Cardiovascular Research, 2015, 107, 78-88.	3.8	13
146	CARMEN, a human super enhancer-associated long noncoding RNA controlling cardiac specification, differentiation and homeostasis. Journal of Molecular and Cellular Cardiology, 2015, 89, 98-112.	1.9	223
147	Prognostic Relevance of Gene-Environment Interactions in Patients WithÂDilated Cardiomyopathy. Journal of the American College of Cardiology, 2015, 66, 1313-1323.	2.8	76
148	Genome-wide profiling of the cardiac transcriptome after myocardial infarction identifies novel heart-specific long non-coding RNAs. European Heart Journal, 2015, 36, 353-368.	2.2	244
149	Small but Smart. , 2015, , 179-190.		1
150	microRNA-122 down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF-Î²1 up-regulation. Clinical Science, 2014, 126, 497-506.	4.3	80
151	<scp>ESC</scp> Working Group on Myocardial Function Position Paper: how to study the right ventricle in experimental models. European Journal of Heart Failure, 2014, 16, 509-518.	7.1	11
152	Targeting myocardial remodelling to develop novel therapies for heart failure. European Journal of Heart Failure, 2014, 16, 494-508.	7.1	90
153	Lymphocytes Infiltrate the Quadriceps Muscle in Lymphocytic Myocarditis Patients: A Potential New Diagnostic Tool. Canadian Journal of Cardiology, 2014, 30, 1547-1554.	1.7	5
154	Fibrosis or hypertrophy: let TIMPs decide. Cardiovascular Research, 2014, 103, 196-197.	3.8	8
155	Diagnostic approach of myocarditis: strike the golden mean. Netherlands Heart Journal, 2014, 22, 80-84.	0.8	12
156	Myocardial Extracellular Matrix. Circulation Research, 2014, 114, 872-888.	4.5	301
157	Peroxidasin-like protein: expanding the horizons of matrix biology. Cardiovascular Research, 2014, 101, 342-343.	3.8	4
158	Meeting highlights from the 2013 <scp>E</scp>uropean <scp>S</scp>ociety of <scp>C</scp>ardiology <scp>H</scp>eart <scp>F</scp>ailure <scp>A</scp>ssociation <scp>W</scp>inter <scp>M</scp>eeting on <scp>T</scp>ranslational <scp>H</scp>eart <scp>F</scp>ailure <scp>R</scp>esearch. European Journal of Heart Failure, 2014, 16, 6-14.	7.1	1
159	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. European Heart Journal, 2014, 35, 2733-2779.	2.2	3,469
160	A passionate endurance cyclist ultimately survives sudden death in right ventricular giant cell myocarditis. International Journal of Cardiology, 2014, 170, e74-e75.	1.7	3
161	Endothelial NADPH Oxidase-2 Promotes Interstitial Cardiac Fibrosis and Diastolic Dysfunction Through Proinflammatory Effects and Endothelial-Mesenchymal Transition. Journal of the American College of Cardiology, 2014, 63, 2734-2741.	2.8	154
162	Heart â€˜omicsâ€™ in AGEing (HOMAGE): design, research objectives and characteristics of the common database. Journal of Biomedical Research, 2014, 28, 349.	1.6	24

#	Article	IF	Citations
163	Matricellular proteins and matrix metalloproteinases mark the inflammatory and fibrotic response in human cardiac allograft rejection. European Heart Journal, 2013, 34, 1930-1941.	2.2	25
164	Macrophage MicroRNA-155 Promotes Cardiac Hypertrophy and Failure. Circulation, 2013, 128, 1420-1432.	1.6	225
165	Mutations in MYH7 reduce the force generating capacity of sarcomeres in human familial hypertrophic cardiomyopathy. Cardiovascular Research, 2013, 99, 432-441.	3.8	102
166	STAT3 activity is necessary and sufficient for the development of immuneâ€mediated myocarditis in mice and promotes progression to dilated cardiomyopathy. EMBO Molecular Medicine, 2013, 5, 572-590.	6.9	44
167	Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure. Nature Cell Biology, 2013, 15, 1282-1293.	10.3	126
168	MicroRNAs as Biomarkers for Ischemic Heart Disease. Journal of Cardiovascular Translational Research, 2013, 6, 458-470.	2.4	24
169	Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2013, 34, 2636-2648.	2.2	2,436
170	A Deep Sequencing Approach to Uncover the miRNOME in the Human Heart. PLoS ONE, 2013, 8, e57800.	2.5	88
171	Role of Inflammation and Matrix Proteinases in Cardiac Remodeling Following Stress and Injury. , 2013, , 179-200.		0
172	Role of SPARC in Cardiac Extracellular Matrix Remodeling After Myocardial Infarction. , 2013, , 427-444.		0
173	CD40â€CD40 ligand (CD40L) signaling modulates cardiac hypertrophy in angiotensinâ€II induced hypertensive heart disease. FASEB Journal, 2013, 27, 1128.6.	0.5	1
174	Osteoglycin (OGN) modulates inflammation during viral myocarditis via an interaction with Toll Like Receptor 4.. FASEB Journal, 2013, 27, 829.1.	0.5	0
175	MicroRNA Profiling Identifies MicroRNA-155 as an Adverse Mediator of Cardiac Injury and Dysfunction During Acute Viral Myocarditis. Circulation Research, 2012, 111, 415-425.	4.5	184
176	Association of left ventricular mass with the AGTR1 A1166C polymorphism. American Journal of Hypertension, 2012, 25, 472-478.	2.0	21
177	Virus Infection of the Heart â€“ Unmet Therapeutic Needs. Antiviral Chemistry and Chemotherapy, 2012, 22, 249-253.	0.6	11
178	Differences in Virus Prevalence and Load in the Hearts of Patients with Idiopathic Dilated Cardiomyopathy with and without Immune-Mediated Inflammatory Diseases. Vaccine Journal, 2012, 19, 1182-1187.	3.1	23
179	MicroRNAs Are Involved in End-Organ Damage During Hypertension. Hypertension, 2012, 60, 1088-1093.	2.7	41
180	Small but smart--microRNAs in the centre of inflammatory processes during cardiovascular diseases, the metabolic syndrome, and ageing. Cardiovascular Research, 2012, 93, 605-613.	3.8	83

#	Article	IF	Citations
181	Thrombospondin-2 prevents cardiac injury and dysfunction in viral myocarditis through the activation of regulatory T-cells. Cardiovascular Research, 2012, 94, 115-124.	3.8	64
182	Use of Circulating MicroRNAs to Diagnose Acute Myocardial Infarction. Clinical Chemistry, 2012, 58, 559-567.	3.2	239
183	Inflammation in viral myocarditis: friend or foe?. Trends in Molecular Medicine, 2012, 18, 426-437.	6.7	111
184	Interactions between the extracellular matrix and inflammation during viral myocarditis. Immunobiology, 2012, 217, 503-510.	1.9	23
185	Idiopathic dilated cardiomyopathy: possible triggers and treatment strategies. Netherlands Heart Journal, 2012, 20, 332-335.	0.8	40
186	Hematopoietic miR155 Deficiency Enhances Atherosclerosis and Decreases Plaque Stability in Hyperlipidemic Mice. PLoS ONE, 2012, 7, e35877.	2.5	129
187	The matricellular proteins thrombospondinâ€2, osteonectin and osteoglycin modulate cardiac inflammation, injury and function during viral myocarditis.. FASEB Journal, 2012, 26, 1060.6.	0.5	0
188	Integrating Cardiac PIP3 and cAMP Signaling through a PKA Anchoring Function of p110Î³. Molecular Cell, 2011, 42, 84-95.	9.7	174
189	Absence of thrombospondin-2 increases cardiomyocyte damage and matrix disruption in doxorubicin-induced cardiomyopathy. Journal of Molecular and Cellular Cardiology, 2011, 51, 318-328.	1.9	43
190	MicroRNAâ€18 and microRNAâ€19 regulate CTGF and TSPâ€1 expression in ageâ€related heart failure. Aging Cell, 2011, 10, 769-779.	6.7	218
191	MicroRNA Involvement in Immune Activation During Heart Failure. Cardiovascular Drugs and Therapy, 2011, 25, 161-170.	2.6	31
192	Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2011, 13, 1-10.	7.1	350
193	Response to Letter Regarding Article, â€œCirculating MicroRNA-208b and MicroRNA-499 Reflect Myocardial Damage in Cardiovascular Diseaseâ€. Circulation: Cardiovascular Genetics, 2011, 4, .	5.1	2
194	Thrombospondin 1. Hypertension, 2011, 58, 770-771.	2.7	5
195	Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. Nature Medicine, 2011, 17, 1610-1618.	30.7	220
196	Diastolic heart failure after acute myocarditis, a new discovery in inflammatory cardiomyopathies?. Heart, 2011, 97, 685-686.	2.9	3
197	Cardiomyocyte disintegration during Andersonâ€“Fabry's disease. European Heart Journal, 2010, 31, 917-917.	2.2	0
198	Intravenous immunoglobulin therapy for patients with idiopathic cardiomyopathy and endomyocardial biopsy-proven high PVB19 viral load. Antiviral Therapy, 2010, 15, 193-201.	1.0	86

#	Article	IF	Citations
199	Parvovirus-B19-associated fulminant myocarditis successfully treated with immunosuppressive and antiviral therapy. Antiviral Therapy, 2010, 15, 681-685.	1.0	13
200	Cardiac involvement in Churgâ€Strauss syndrome. Arthritis and Rheumatism, 2010, 62, 627-634.	6.7	158
201	Circulating MicroRNA-208b and MicroRNA-499 Reflect Myocardial Damage in Cardiovascular Disease. Circulation: Cardiovascular Genetics, 2010, 3, 499-506.	5.1	683
202	Syndecan-1 Amplifies Angiotensin Iiâ€"Induced Cardiac Fibrosis. Hypertension, 2010, 55, 249-256.	2.7	69
203	Matricellular Signaling Molecule CCN1 Attenuates Experimental Autoimmune Myocarditis by Acting as a Novel Immune Cell Migration Modulator. Circulation, 2010, 122, 2688-2698.	1.6	56
204	Regulation of Cardiac Gene Expression by KLF15, a Repressor of Myocardin Activity. Journal of Biological Chemistry, 2010, 285, 27449-27456.	3.4	48
205	Replacement and reactive myocardial fibrosis in idiopathic dilated cardiomyopathy: comparison of magnetic resonance imaging with right ventricular biopsy. European Journal of Heart Failure, 2010, 12, 227-231.	7.1	66
206	Cardiac extracellular matrix remodeling: Fibrillar collagens and Secreted Protein Acidic and Rich in Cysteine (SPARC). Journal of Molecular and Cellular Cardiology, 2010, 48, 544-549.	1.9	93
207	TIMPs and cardiac remodeling: â€˜Embracing the MMP-independent-side of the familyâ€™. Journal of Molecular and Cellular Cardiology, 2010, 48, 445-453.	1.9	118
208	MicroRNAs and Beyond. Hypertension, 2009, 54, 1189-1194.	2.7	37
209	Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2009, 11, 119-129.	7.1	281
210	Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction. Journal of Experimental Medicine, 2009, 206, 113-123.	8.5	180
211	Absence of Thrombospondin-2 Causes Age-Related Dilated Cardiomyopathy. Circulation, 2009, 120, 1585-1597.	1.6	92
212	Thrombospondins in the heart: potential functions in cardiac remodeling. Journal of Cell Communication and Signaling, 2009, 3, 201-213.	3.4	42
213	miR-133 and miR-30 Regulate Connective Tissue Growth Factor. Circulation Research, 2009, 104, 170-178.	4.5	763
214	Factor XIII: the cement of the heart after myocardial infarction?. European Heart Journal, 2008, 29, 427-428.	2.2	11
215	Letter by Pinto and Heymans Regarding Article, â€œAblation of Matrix Metalloproteinase-9 Increases Severity of Viral Myocarditis in Miceâ€• Circulation, 2008, 118, e697.	1.6	2
216	Acute viral myocarditis. European Heart Journal, 2008, 29, 2073-2082.	2.2	339

#	Article	IF	Citations
217	Increased Expression of Syndecan-1 Protects Against Cardiac Dilatation and Dysfunction After Myocardial Infarction. Circulation, 2007, 115, 475-482.	1.6	123
218	Lysosomal integral membrane protein 2 is a novel component of the cardiac intercalated disc and vital for load-induced cardiac myocyte hypertrophy. Journal of Experimental Medicine, 2007, 204, 1227-1235.	8.5	37
219	Myocarditis and heart failure: need for better diagnostic, predictive, and therapeutic tools. European Heart Journal, 2007, 28, 1279-1280.	2.2	29
220	Annexin A5 and the failing heart; lost or found in translation?. European Heart Journal, 2007, 28, 2695-2696.	2.2	3
221	Kruppel-like factor 15 is a regulator of cardiomyocyte hypertrophy. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 7074-7079.	7.1	186
222	How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. European Heart Journal, 2007, 28, 2539-2550.	2.2	2,302
223	Lysosomal integral membrane protein 2 is a novel component of the cardiac intercalated disc and vital for load-induced cardiac myocyte hypertrophy. Journal of Cell Biology, 2007, 177, i5-i5.	5.2	0
224	Imatinib Attenuates End-Organ Damage in Hypertensive Homozygous TGR(mRen2)27 Rats. Hypertension, 2006, 47, 467-474.	2.7	54
225	Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: A temporal and spatial window. Cardiovascular Research, 2006, 69, 604-613.	3.8	227
226	Inhibition of Urokinase-Type Plasminogen Activator or Matrix Metalloproteinases Prevents Cardiac Injury and Dysfunction During Viral Myocarditis. Circulation, 2006, 114, 565-573.	1.6	100
227	Increased Cardiac Expression of Tissue Inhibitor of Metalloproteinase-1 and Tissue Inhibitor of Metalloproteinase-2 Is Related to Cardiac Fibrosis and Dysfunction in the Chronic Pressure-Overloaded Human Heart. Circulation, 2005, 112, 1136-1144.	1.6	267
228	Loss or Inhibition of uPA or MMP-9 Attenuates LV Remodeling and Dysfunction after Acute Pressure Overload in Mice. American Journal of Pathology, 2005, 166, 15-25.	3.8	150
229	Thrombospondin-2 Is Essential for Myocardial Matrix Integrity. Circulation Research, 2004, 95, 515-522.	4.5	179
230	Matricellular proteins in the heart: possible role during stress and remodeling. Cardiovascular Research, 2004, 64, 24-31.	3.8	166
231	Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nature Genetics, 2001, 28, 131-138.	21.4	967
232	Replacement of the Muscle-Specific Sarcoplasmic Reticulum Ca 2+ -ATPase Isoform SERCA2a by the Nonmuscle SERCA2b Homologue Causes Mild Concentric Hypertrophy and Impairs Contraction-Relaxation of the Heart. Circulation Research, 2001, 89, 838-846.	4.5	93
233	Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes. Blood, 2000, 96, 1425-1432.	1.4	64
234	Outcome and One Year Follow-up of Intra-arterial Staphylokinase in 191 Patients with Peripheral Arterial Occlusion. Thrombosis and Haemostasis, 2000, 83, 666-671.	3.4	34

#	Article	IF	Citations
235	Disruption of the Plasminogen Gene in Mice Abolishes Wound Healing after Myocardial Infarction. American Journal of Pathology, 2000, 156, 1865-1873.	3.8	134
236	Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes. Blood, 2000, 96, 1425-1432.	1.4	3
237	Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nature Medicine, 1999, 5, 1135-1142.	30.7	745
238	Feasibility Study of Catheter-directed Thrombolysis with Recombinant Staphylokinase in Deep Venous Thrombosis. Thrombosis and Haemostasis, 1998, 79, 517-519.	3.4	17